🚀 VC round data is live in beta, check it out!
Instil Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Instil Bio and similar public comparables like TScan Therapeutics, Circio Holding, InflaRx, NRX Pharmaceuticals and more.
Instil Bio Overview
About Instil Bio
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Founded
2018
HQ
Employees
14
Website
Sectors
Financials (LTM)
EV
$66M
Instil Bio Financials
Instil Bio reported last 12-month revenue of —.
In the same LTM period, Instil Bio generated had net loss of ($68M).
Revenue (LTM)
Instil Bio P&L
In the most recent fiscal year, Instil Bio reported revenue of — and EBITDA of ($63M).
Instil Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($63M) | XXX | XXX | XXX |
| Net Profit | ($68M) | XXX | ($74M) | XXX | XXX | XXX |
| Net Debt | — | — | $75M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Instil Bio Stock Performance
Instil Bio has current market cap of $61M, and enterprise value of $66M.
Market Cap Evolution
Instil Bio's stock price is $9.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $66M | $61M | 0.0% | XXX | XXX | XXX | $-10.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInstil Bio Valuation Multiples
Instil Bio trades at (1.1x) EV/EBITDA.
EV / Revenue (LTM)
Instil Bio Financial Valuation Multiples
As of March 18, 2026, Instil Bio has market cap of $61M and EV of $66M.
Equity research analysts estimate Instil Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Instil Bio has a P/E ratio of (0.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $61M | XXX | $61M | XXX | XXX | XXX |
| EV (current) | $66M | XXX | $66M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.9x) | XXX | (1.2x) | XXX | XXX | XXX |
| P/E | (0.9x) | XXX | (0.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Instil Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Instil Bio Margins & Growth Rates
Instil Bio's revenue in the last fiscal year grew by —.
Instil Bio's revenue per employee in the last FY averaged $0.0M.
Instil Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (57%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Instil Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| TScan Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Circio Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| InflaRx | XXX | XXX | XXX | XXX | XXX | XXX |
| NRX Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Instil Bio M&A Activity
Instil Bio acquired XXX companies to date.
Last acquisition by Instil Bio was on XXXXXXXX, XXXXX. Instil Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Instil Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInstil Bio Investment Activity
Instil Bio invested in XXX companies to date.
Instil Bio made its latest investment on XXXXXXXX, XXXXX. Instil Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Instil Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Instil Bio
| When was Instil Bio founded? | Instil Bio was founded in 2018. |
| Where is Instil Bio headquartered? | Instil Bio is headquartered in United States. |
| How many employees does Instil Bio have? | As of today, Instil Bio has over 14 employees. |
| Who is the CEO of Instil Bio? | Instil Bio's CEO is Bronson Crouch. |
| Is Instil Bio publicly listed? | Yes, Instil Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Instil Bio? | Instil Bio trades under TIL ticker. |
| When did Instil Bio go public? | Instil Bio went public in 2021. |
| Who are competitors of Instil Bio? | Instil Bio main competitors are TScan Therapeutics, Circio Holding, InflaRx, NRX Pharmaceuticals. |
| What is the current market cap of Instil Bio? | Instil Bio's current market cap is $61M. |
| Is Instil Bio profitable? | No, Instil Bio is not profitable. |
| What is the current net income of Instil Bio? | Instil Bio's last 12 months net income is ($68M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.